Table 2.
Clinical information of KHP PCaBB participants from Jan 2013-Dec 2015
| Clinical Variable | Consented (n = 549) |
|---|---|
| Treatment type | |
| Surgery | 357 (65.0) |
| Active Monitoring | 74 (13.5) |
| Anti-cancer drug regimen (Hormone Therapy) | 98 (17.9) |
| Anti-cancer drug regimen (Cytotoxic Chemotherapy) | 2 (0.4) |
| Brachytherapy | 18 (3.3) |
| Specialist palliative care | 0 (0.0) |
| Mean PSA (SD) at diagnosis (μg/L) | 42.77 (±374.927) |
| Gleason Score | |
| 6 | 74 (13.5) |
| 7 | 358 (65.2) |
| 8 | 44 (8.0) |
| 9 | 53 (9.7) |
| 10 | 3 (0.5) |
| Unrecorded | 19 (3.5) |
| Gleason Group | |
| Grade 1 | 74 (13.5) |
| Grade 2 | 247 (45.0) |
| Grade 3 | 111 (20.2) |
| Grade 4 | 44 (8.0) |
| Grade 5 | 56 (10.2) |
| T stage | |
| TX | 42 (7.7) |
| T0 | 28 (5.1) |
| T1 | 4 (0.7) |
| T1a | 2 (0.4) |
| T1b | 0 (0.0) |
| T1c | 16 (2.9) |
| T2 | 106 (19.3) |
| T2a | 153 (27.9) |
| T2b | 15 (2.7) |
| T2c | 60 (10.9) |
| T3 | 17 (3.1) |
| T3a | 69 (12.6) |
| T3b | 34 (6.2) |
| T4 | 3 (0.5) |
| T4a | 0 (0.0) |
| N stage | |
| NX | 191 (34.8) |
| N0 | 334 (60.8) |
| N1 | 24 (4.4) |
| N2 | 0 (0.0) |
| M stage | |
| MX | 221 (40.3) |
| M0 | 315 (57.4) |
| M1 | 5 (0.9) |
| M1a | 1 (0.2) |
| M1b | 5 (0.9) |
| M1c | 2 (0.4) |
| Risk Category | |
| Localised prostate cancer | |
| Low risk | 83 (15.1) |
| Intermediate risk | 252 (45.9) |
| High Risk | 157 (28.6) |
| Regionally metastatic/ Locally advanced | 23 (4.2) |
| Distant metastasis | 25 (4.6) |
| Unrecorded | 9 (1.6) |
| Comorbidities | |
| Mean number of comorbidities (SD) | 1.9 (±2.021) |
| Previous/other cancer | 20 (3.6) |
| Cardiovascular disease | 218 (39.7) |
| HIV or Infectious Diseases | 5 (0.9) |
| Hyperlipidaemia and hypercholesterolemia | 87 (4.8) |
| Diabetes | 68 (3.8) |
| Psychological | 32 (5.8) |
| Mean number of medications (SD) | 2.213 (±2.529) |
| Erectile dysfunction medication | 216 (39.3) |
| Outcome | |
| Disease stable | 444 (80.9) |
| Discharged to GP | 56 (10.2) |
| Treatment discharged to GP | 17 (3.1) |
| Discharged to different hospital | 4 (0.7) |
| Progression | 7 (1.3) |
| Progression to metastasis | 3 (0.5) |
| Recurrence | 2 (0.4) |
| Death | 6 (1.1) |
| Awaiting treatment | 2 (0.4) |
| Refused further treatment | 1 (0.2) |
| Treated privately | 1 (0.2) |
| Lost to follow up | 6 (1.1) |
| Involvement in clinical trial | 34 (6.2) |